Research progress of long non-coding RNA DLEU1 in malignant tumors

doi:10.3760/cma.j.cn371439-20250523-00121

Abstract

Abstract:

Long non-coding RNA DLEU1 has emerged as a novel key molecule in pan-cancer research， potentially playing a critical role in regulating the occurrence and progression of malignant tumors. Although studies on DLEU1 remain limited， recent researches have confirmed its aberrant expression in various malignancies. DLEU1 can regulate the malignant phenotype of tumor cells through competitive endogenous RNA mechanisms， epigenetic regulation， and transcriptional feedback loops， including proliferation， migration， invasion， and chemoresistance， which are closely associated with poor prognosis. Additionally， its enrichment in exosomes suggests its potential as a diagnostic biomarker. Systematic analysis and exploration of the expression regulation and mechanism of action of DLEU1 in various malignant tumors can deeply understand the biological mechanisms such as the spatio-temporal heterogeneity， targeted treatment strategies， and interaction with the microenvironment of DLEU1 in malignant tumors， providing reference and guidance for precise tumor treatment and basic research applications based on non-coding RNA.

Key words: RNA， long noncoding, Biomarkers， tumor, Epigenomics, Tumor heterogeneity, Competing endogenous RNA

Sun Mingzhu, Liu Yanquan, Sun Lei, Tang Huanwen. Research progress of long non-coding RNA DLEU1 in malignant tumors[J]. Journal of International Oncology, 2025, 52(11): 708-713.

References 52

[1]	Xu K, Xia P, Chen X, et al. ncRNA-mediated fatty acid metabolism reprogramming in HCC[J]. Trends Endocrinol Metab, 2023, 34(5): 278-291. DOI: 10.1016/j.tem.2023.02.007.
[2]	Tan YT, Lin JF, Li T, et al. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer[J]. Cancer Commun (Lond), 2021, 41(2): 109-120. DOI: 10.1002/cac2.12108.
[3]	Zhang Y. LncRNA-encoded peptides in cancer[J]. J Hematol Oncol, 2024, 17(1): 66. DOI: 10.1186/s13045-024-01591-0.
[4]	Edelmann J, Holzmann K, Miller F, et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations[J]. Blood, 2012, 120(24): 4783-4794. DOI: 10.1182/blood-2012-04-423517. pmid: 23047824
[5]	Lv T, Liu H, Wu Y, et al. Knockdown of lncRNA DLEU1 inhibits the tumorigenesis of oral squamous cell carcinoma via regulation of miR‑149‑5p/CDK6 axis[J]. Mol Med Rep, 2021, 23(6): 447. DOI: 10.3892/mmr.2021.12086.
[6]	吴昊, 张慧, 何海燕, 等. 532例多发性骨髓瘤患者细胞遗传学异常及对预后的影响[J]. 中华血液学杂志, 2017, 38(9): 739-743. DOI: 10.3760/cma.j.issn.0253-2727.2017.09.002.
[7]	Hallek M. Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy[J]. Am J Hematol, 2025, 100(3): 450-480. DOI: 10.1002/ajh.27546.
[8]	Garding A, Bhattacharya N, Claus R, et al. Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-κB[J]. PLoS Genet, 2013, 9(4): e1003373. DOI: 10.1371/journal.pgen.1003373.
[9]	Srinivasan VK, Naseem S, Varma N, et al. Genomic alterations in chronic lymphocytic leukemia and their correlation with clinico-hematological parameters and disease progression[J]. Blood Res, 2020, 55(3): 131-138. DOI: 10.5045/br.2020.2020080. pmid: 32747613
[10]	Crombie J, LaCasce A. The treatment of Burkitt lymphoma in adults[J]. Blood, 2021, 137(6): 743-750. DOI: 10.1182/blood.201900 4099. pmid: 33171490
[11]	Lee S, Luo W, Shah T, et al. The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL[J]. Oncotarget, 2017, 8(17): 27839-27853. DOI: 10.18632/oncotarget.15711. pmid: 28427156
[12]	Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies[J]. Nat Rev Drug Discov, 2013, 12(3): 229-243. DOI: 10.1038/nrd3937. pmid: 23449308
[13]	Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention[J]. Nat Rev Clin Oncol, 2023, 20(5): 338-349. DOI: 10.1038/s41571-023-00747-0. pmid: 36959359
[14]	Ghodrati R, Safaralizadeh R, Dastmalchi N, et al. Overexpression of lncRNA DLEU1 in gastric cancer tissues compared to adjacent non-tumor tissues[J]. J Gastrointest Cancer, 2022, 53(4): 990-994. DOI: 10.1007/s12029-021-00733-8.
[15]	Xu H, Ba Z, Liu C, et al. Long noncoding RNA DLEU1 promotes proliferation and glycolysis of gastric cancer cells via APOC1 upregulation by recruiting SMYD2 to induce trimethylation of H3K4 modification[J]. Transl Oncol, 2023, 36: 101731. DOI: 10.1016/j.tranon.2023.101731.
[16]	Wang Y, Xu M, Liu C, et al. Induction of ferroptosis by shikonin in gastric cancer via the DLEU1/mTOR/GPX4 axis[J]. Cell Biol Int, 2025, 49(7): 757-771. DOI: 10.1002/cbin.70018.
[17]	WHO. Colorectal cancer[EB/OL]. (2023-07-11) [2025-03-02]. https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer.
[18]	Zhuge W, Chen R, Vladimir K, et al. Costunolide specifically binds and inhibits thioredoxin reductase 1 to induce apoptosis in colon cancer[J]. Cancer Lett, 2018, 412: 46-58. DOI: 10.1016/j.canlet.2017.10.006. pmid: 29037867
[19]	Liu T, Han Z, Li H, et al. LncRNA DLEU1 contributes to colorectal cancer progression via activation of KPNA3[J]. Mol Cancer, 2018, 17(1): 118. DOI: 10.1186/s12943-018-0873-2. pmid: 30098595
[20]	Li Q, Zhang Z, Jiang H, et al. DLEU1 promotes cell survival by preventing DYNLL1 degradation in esophageal squamous cell carcinoma[J]. J Transl Med, 2022, 20(1): 245. DOI: 10.1186/s12967-022-03449-w. pmid: 35619131
[21]	Chen R, Zheng R, Zhang S, et al. Patterns and trends in esophageal cancer incidence and mortality in China: an analysis based on cancer registry data[J]. J Natl Cancer Cent, 2023, 3(1): 21-27. DOI: 10.1016/j.jncc.2023.01.002.
[22]	Liu Z, Zhao Y, Kong P, et al. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma[J]. Cancer Cell, 2023, 41(1): 181-195.e9. DOI: 10.1016/j.ccell.2022.12.004. pmid: 36584672
[23]	食管癌筛查与早诊早治方案(2024年版)[J]. 国际肿瘤学杂志, 2025, 52(1): 1-2. DOI: 10.3760/cma.j.cn371439-20240621-00001.
[24]	Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400(10360): 1345-1362. DOI: 10.1016/S0140-6736(22)01200-4. pmid: 36084663
[25]	Zhang W, Liu S, Liu K, et al. Long non-coding RNA deleted in lymphocytic leukaemia 1 promotes hepatocellular carcinoma progression by sponging miR-133a to regulate IGF-1R expression[J]. J Cell Mol Med, 2019, 23(8): 5154-5164. DOI: 10.1111/jcmm.14384. pmid: 31207081
[26]	Raggi C, Taddei ML, Rae C, et al. Metabolic reprogramming in cholangiocarcinoma[J]. J Hepatol, 2022, 77(3): 849-864. DOI: 10.1016/j.jhep.2022.04.038. pmid: 35594992
[27]	Li J, Jiang X, Xu Y, et al. YY1-induced DLEU1/miR-149-5p promotes malignant biological behavior of cholangiocarcinoma through upregulating YAP1/TEAD2/SOX2[J]. Int J Biol Sci, 2022, 18(11): 4301-4315. DOI: 10.7150/ijbs.66224. pmid: 35864972
[28]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[29]	孔北华, 宋坤, 殷爱军. 重视子宫内膜癌的防治[J]. 中华医学杂志, 2024, 104(10): 715-720. DOI: 10.3760/cma.j.cn112137-20230927-00587.
[30]	Shao W, Li Y, Chen F, et al. Long non-coding RNA DLEU1 contributes to the development of endometrial cancer by sponging miR-490 to regulate SP1 expression[J]. Pharmazie, 2018, 73(7): 379-385. DOI: 10.1691/ph.2018.8352. pmid: 30001771
[31]	Du Y, Wang L, Chen S, et al. lncRNA DLEU1 contributes to tumorigenesis and development of endometrial carcinoma by targeting mTOR[J]. Mol Carcinog, 2018, 57(9): 1191-1200. DOI: 10.1002/mc.22835.
[32]	Ali AT, Al-Ani O, Al-Ani F. Epidemiology and risk factors for ovarian cancer[J]. Prz Menopauzalny, 2023, 22(2): 93-104. DOI: 10.5114/pm.2023.128661. pmid: 37674925
[33]	Cho KR, Shih IeM. Ovarian cancer[J]. Annu Rev Pathol, 2009, 4: 287-313. DOI: 10.1146/annurev.pathol.4.110807.092246. pmid: 18842102
[34]	Wang LL, Sun KX, Wu DD, et al. DLEU1 contributes to ovarian carcinoma tumourigenesis and development by interacting with miR-490-3p and altering CDK1 expression[J]. J Cell Mol Med, 2017, 21(11): 3055-3065. DOI: 10.1111/jcmm.13217.
[35]	Xu H, Wang L, Jiang X. Silencing of lncRNA DLEU1 inhibits tumorigenesis of ovarian cancer via regulating miR-429/TFAP2A axis[J]. Mol Cell Biochem, 2021, 476(2): 1051-1061. DOI: 10.1007/s11010-020-03971-9. pmid: 33170430
[36]	Xu H, Xu B. Breast cancer: epidemiology, risk factors and screening[J]. Chin J Cancer Res, 2023, 35(6): 565-583. DOI: 10.21147/j.issn.1000-9604.2023.06.02.
[37]	Pang B, Sui S, Wang Q, et al. Upregulation of DLEU1 expression by epigenetic modification promotes tumorigenesis in human cancer[J]. J Cell Physiol, 2019, 234(10): 17420-17432. DOI: 10.1002/jcp.28364. pmid: 30793303
[38]	Ma HN, Chen HJ, Liu JQ, et al. Long non-coding RNA DLEU1 promotes malignancy of breast cancer by acting as an indispensable coactivator for HIF-1α-induced transcription of CKAP2[J]. Cell Death Dis, 2022, 13(7): 625. DOI: 10.1038/s41419-022-04880-z. pmid: 35853854
[39]	Wang C, Xie XX, Li WJ, et al. LncRNA DLEU1/microRNA-300/RAB22A axis regulates migration and invasion of breast cancer cells[J]. Eur Rev Med Pharmacol Sci, 2019, 23(23): 10410-10421. DOI: 10.26355/eurrev_201912_19680.
[40]	P J N, Patil SR, Veeraraghavan VP, et al. Oral cancer stem cells: a comprehensive review of key drivers of treatment resistance and tumor recurrence[J]. Eur J Pharmacol, 2025, 989: 177222. DOI: 10.1016/j.ejphar.2024.177222.
[41]	Sun KD, Ni YJ, Qin H, et al. LncRNA DLEU1 facilitates the progression of oral squamous cell carcinoma by miR-126-5p/GAB1 axis[J]. Kaohsiung J Med Sci, 2022, 38(10): 950-959. DOI: 10.1002/kjm2.12572.
[42]	Riely GJ, Wood DE, Ettinger DS, et al. Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2024, 22(4): 249-274. DOI: 10.6004/jnccn.2204.0023.
[43]	史文俊, 李芳, 安黎云. 非小细胞肺癌患者血清Hsa_circ_0007142表达及其临床价值[J]. 肿瘤学杂志, 2025, 31(5): 385-389. DOI: 10.11735/j.issn.1671-170x.2025.05.B003.
[44]	李丹, 李睿尧, 李膺函, 等. 血清miR-19b、miR-744-5p水平在非小细胞肺癌诊断中的临床价值[J]. 国际肿瘤学杂志, 2024, 51(2): 83-88. DOI: 10.3760/cma.j.cn371439-20230308-00011.
[45]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. DOI: 10.3322/caac.21654.
[46]	Zhang S, Guan Y, Liu X, et al. Long non-coding RNA DLEU1 exerts an oncogenic function in non-small cell lung cancer[J]. Biomed Pharmacother, 2019, 109: 985-990. DOI: 10.1016/j.biopha.2018.10.175. pmid: 30551552
[47]	Trifănescu OG, Trifănescu RA, Mitrică R, et al. Upstaging and downstaging in gliomas-clinical implications for the fifth edition of the World Health Organization classification of tumors of the central nervous system[J]. Diagnostics (Basel), 2023, 13(2): 197. DOI: 10.3390/diagnostics13020197.
[48]	Liu X, Chen R, Liu L. SP1-DLEU1-miR-4429 feedback loop promotes cell proliferative and anti-apoptotic abilities in human glioblastoma[J]. Biosci Rep, 2019, 39(12): BSR20190994. DOI: 10.1042/BSR20190994.
[49]	Liu X, Song J, Zhou Z, et al. Establishment of an alternative splicing prognostic risk model and identification of FN1 as a potential biomarker in glioblastoma multiforme[J]. Sci Rep, 2025, 15(1): 6716. DOI: 10.1038/s41598-025-91038-4.
[50]	Bian J, Liu Y, Zhao X, et al. Research progress in the mechanism and treatment of osteosarcoma[J]. Chin Med J (Engl), 2023, 136(20): 2412-2420. DOI: 10.1097/CM9.0000000000002800.
[51]	Chen X, Zhang C, Wang X. Long noncoding RNA DLEU1 aggravates osteosarcoma carcinogenesis via regulating the miR-671-5p/DDX5 axis[J]. Artif Cells Nanomed Biotechnol, 2019, 47(1): 3322-3328. DOI: 10.1080/21691401.2019.1648285. pmid: 31379208
[52]	Giraud G, Terrone S, Bourgeois CF. Functions of DEAD box RNA helicases DDX5 and DDX17 in chromatin organization and transcriptional regulation[J]. BMB Rep, 2018, 51(12): 613-622. DOI: 10.5483/BMBRep.2018.51.12.234. pmid: 30293550